ACT OLANZAPINE ODT 10 MG
OLANZAPINE : 10 MG · DIN 02327570 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is ACT OLANZAPINE ODT?
ACT OLANZAPINE ODT 10 MG contains OLANZAPINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02327570, held by TEVA CANADA LIMITED, supplied as TABLET (ORALLY DISINTEGRATING) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Jan-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT OLANZAPINE ODT used for?
Acute and maintenance treatment of schizophrenia and related psychotic disorders; acute treatment of manic or mixed episodes in bipolar I disorder (monotherapy or cotherapy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02327570 |
|---|---|
| Brand name | ACT OLANZAPINE ODT |
| Generic / active ingredient | OLANZAPINE : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AH03 OLANZAPINE |
| AHFS class | 28:16.08.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Jan-2021 |
| Original market date | 2009-10-16 00:00:00 |
How is it administered?
Schizophrenia: Acute and maintenance treatment. Bipolar: Monotherapy or cotherapy (lithium/divalproex). Recommended starting dose 5 mg QD to minimize risk of orthostatic hypotension.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refers to STORAGE AND STABILITY section which is listed in TOC but text is cut off).
How is it supplied?
Not explicitly detailed in the provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section which is listed in TOC but text is cut off).
Contraindications
Known hypersensitivity to the drug or the excipients of the product.
Warnings and precautions
Increased mortality in elderly patients with dementia. Neuroleptic Malignant Syndrome (NMS), weight gain, hyperglycaemia, lipids increases, TD, and DRESS.
Is OLANZAPINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AH03 OLANZAPINE. 103 of 271 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OLANZAPINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02281821 |
| APO-OLANZAPINE | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02281848 |
| APO-OLANZAPINE | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281791 |
| APO-OLANZAPINE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02333015 |
| APO-OLANZAPINE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281805 |
| APO-OLANZAPINE | 7.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281813 |
| APO-OLANZAPINE ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360624 |
| APO-OLANZAPINE ODT | 15 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360632 |
| APO-OLANZAPINE ODT | 20 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360640 |
| APO-OLANZAPINE ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360616 |
Who else supplies OLANZAPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OLANZAPINE appears in 1801 registered pack listings across 15 markets, published on 13 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.